Id |
Subject |
Object |
Predicate |
Lexical cue |
TextSentencer_T1 |
0-173 |
Sentence |
denotes |
Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: an exploratory analysis. |
T1 |
0-173 |
Sentence |
denotes |
Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: an exploratory analysis. |
TextSentencer_T2 |
174-296 |
Sentence |
denotes |
Biologics such as TNF antagonists are a new class of drugs that have greatly improved Rheumatoid Arthritis (RA) treatment. |
T2 |
174-296 |
Sentence |
denotes |
Biologics such as TNF antagonists are a new class of drugs that have greatly improved Rheumatoid Arthritis (RA) treatment. |
TextSentencer_T3 |
297-442 |
Sentence |
denotes |
However, for unknown reasons, individual patients with RA respond to one of these drugs but not to others even those targeting the same molecule. |
T3 |
297-442 |
Sentence |
denotes |
However, for unknown reasons, individual patients with RA respond to one of these drugs but not to others even those targeting the same molecule. |
TextSentencer_T4 |
443-635 |
Sentence |
denotes |
Methods to predict response are sorely needed because these drugs are currently selected by trial and error, what is very inefficient and prejudicial for the patient and the healthcare system. |
T4 |
443-635 |
Sentence |
denotes |
Methods to predict response are sorely needed because these drugs are currently selected by trial and error, what is very inefficient and prejudicial for the patient and the healthcare system. |
TextSentencer_T5 |
636-775 |
Sentence |
denotes |
Here, we have explored the discovery of protein biomarkers in serum from patients treated with infliximab, one of the major anti-TNF drugs. |
T5 |
636-775 |
Sentence |
denotes |
Here, we have explored the discovery of protein biomarkers in serum from patients treated with infliximab, one of the major anti-TNF drugs. |
TextSentencer_T6 |
776-862 |
Sentence |
denotes |
The study was based in a quantitative proteomics approach using 8-plex iTRAQ labeling. |
T6 |
776-862 |
Sentence |
denotes |
The study was based in a quantitative proteomics approach using 8-plex iTRAQ labeling. |
TextSentencer_T7 |
863-1048 |
Sentence |
denotes |
It combined depletion of the most abundant serum proteins, two-dimensional LC fractionation, protein identification and relative quantification with a hybrid Orbitrap mass spectrometer. |
T7 |
863-1048 |
Sentence |
denotes |
It combined depletion of the most abundant serum proteins, two-dimensional LC fractionation, protein identification and relative quantification with a hybrid Orbitrap mass spectrometer. |
TextSentencer_T8 |
1049-1173 |
Sentence |
denotes |
This approach allowed the identification of 315 proteins of which 237 were confidently quantified with two or more peptides. |
T8 |
1049-1173 |
Sentence |
denotes |
This approach allowed the identification of 315 proteins of which 237 were confidently quantified with two or more peptides. |
TextSentencer_T9 |
1174-1277 |
Sentence |
denotes |
The detection range covered up to 6 orders of magnitude including multiple proteins at the ng/mL level. |
T9 |
1174-1277 |
Sentence |
denotes |
The detection range covered up to 6 orders of magnitude including multiple proteins at the ng/mL level. |
TextSentencer_T10 |
1278-1407 |
Sentence |
denotes |
A new set of putative biomarkers was identified comprising 14 proteins significantly more abundant in the non-responder patients. |
T10 |
1278-1407 |
Sentence |
denotes |
A new set of putative biomarkers was identified comprising 14 proteins significantly more abundant in the non-responder patients. |
TextSentencer_T11 |
1408-1530 |
Sentence |
denotes |
The differential proteins were enriched in apolipoproteins, components of the complement system and acute phase reactants. |
T11 |
1408-1530 |
Sentence |
denotes |
The differential proteins were enriched in apolipoproteins, components of the complement system and acute phase reactants. |
TextSentencer_T12 |
1531-1794 |
Sentence |
denotes |
These results show the feasibility of this approach and provide a set of candidates for validation as biomarkers for the classification of RA patients before the beginning of treatment, so that anticipated non-responders could be treated with an alternative drug. |
T12 |
1531-1794 |
Sentence |
denotes |
These results show the feasibility of this approach and provide a set of candidates for validation as biomarkers for the classification of RA patients before the beginning of treatment, so that anticipated non-responders could be treated with an alternative drug. |